Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Exelixis Inc (EXEL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,317,170
  • Shares Outstanding, K 300,130
  • Annual Sales, $ 853,830 K
  • Annual Income, $ 690,070 K
  • 60-Month Beta 2.22
  • Price/Sales 8.55
  • Price/Cash Flow 16.03
  • Price/Book 5.65

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 0.25
  • Number of Estimates 7
  • High Estimate 0.30
  • Low Estimate 0.20
  • Prior Year 0.37
  • Growth Rate Est. (year over year) -32.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.07 +14.81%
on 02/22/19
25.31 -4.44%
on 03/18/19
+2.97 (+13.97%)
since 02/21/19
3-Month
17.14 +41.10%
on 12/24/18
25.31 -4.44%
on 03/18/19
+6.47 (+36.48%)
since 12/21/18
52-Week
13.42 +80.22%
on 10/29/18
25.31 -4.44%
on 03/18/19
+0.06 (+0.23%)
since 03/21/18

Most Recent Stories

More News
Exelixis (EXEL) Gains As Market Dips: What You Should Know

Exelixis (EXEL) closed at $24.76 in the latest trading session, marking a +0.2% move from the prior day.

EXEL : 24.20 (-0.74%)
Why Is Exelixis (EXEL) Up 12.1% Since Last Earnings Report?

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

EXEL : 24.20 (-0.74%)
Pfizer's (PFE) Kidney Cancer Drug Combo Gets EMA's Validation

Pfizer's (PFE) application for Bavencio in combination with Inlyta for the treatment of advanced RCC gets validated by EMA.

MRK : 82.89 (+0.99%)
EXEL : 24.20 (-0.74%)
PFE : 42.46 (+0.69%)
BMY : 48.99 (-0.41%)
SmarTrend Watching for Potential Pullback in Shares of Exelixis Inc After 2.17% Gain

Exelixis Inc (NASDAQ:EXEL) traded in a range yesterday that spanned from a low of $23.06 to a high of $23.57. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $23.30...

EXEL : 24.20 (-0.74%)
Exelixis (EXEL) Dips More Than Broader Markets: What You Should Know

Exelixis (EXEL) closed at $23.04 in the latest trading session, marking a -0.39% move from the prior day.

EXEL : 24.20 (-0.74%)
Exelixis Announces Webcasts of Investor Conference Presentations in March

Exelixis, Inc.(NASDAQ: EXEL) today announced thatthe company will be presenting at the following investor conferences in March:

EXEL : 24.20 (-0.74%)
New Strong Sell Stocks for February 15th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

USG : 43.08 (+0.05%)
BABY : 27.06 (+2.31%)
CPE : 7.82 (+1.43%)
EXEL : 24.20 (-0.74%)
LTHM : 13.21 (+4.26%)
Exelixis (EXEL) Earnings, Revenues Beat Estimates in Q4

Exelixis's (EXEL) earnings and revenues beat expectations in the fourth quarter on strong sales of Cabometyx.

EXEL : 24.20 (-0.74%)
RHHBY : 33.9050 (-0.54%)
PFE : 42.46 (+0.69%)
BMY : 48.99 (-0.41%)
Exelixis: 4Q Earnings Snapshot

ALAMEDA, Calif. (AP) _ Exelixis Inc. (EXEL) on Tuesday reported fourth-quarter net income of $360.1 million.

EXEL : 24.20 (-0.74%)
Exelixis (EXEL) Tops Q4 Earnings and Revenue Estimates

Exelixis (EXEL) delivered earnings and revenue surprises of 48.00% and 16.80%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

EXEL : 24.20 (-0.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade EXEL with:

Business Summary

Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ' (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another...

See More

Key Turning Points

2nd Resistance Point 25.04
1st Resistance Point 24.71
Last Price 24.17
1st Support Level 24.13
2nd Support Level 23.88

See More

52-Week High 25.31
Last Price 24.17
Fibonacci 61.8% 20.77
Fibonacci 50% 19.36
Fibonacci 38.2% 17.96
52-Week Low 13.42

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar